Trial reportPsychiatric services (Washington, D.C.)2016
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Registry-linked trialOpen access · bronzeAbstract readComparative StudyRandomized Controlled Trial
In one paragraph
Trial report in Psychiatric services (Washington, D.C.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01136772 (A Comparison of Long-Acting Injectable Medications for Schizophrenia), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Comparison of Long-Acting Injectable Medications for Schizophrenia
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Pooled it
- Healthcare utilization and economics evaluation of paliperidone palmitate once-monthly in schizophrenia: a one-year, real-world, and retrospective mirror image study in China.Frontiers in psychiatry · 2024Article
- Cost-effectiveness analysis of monthly, 3-monthly, and 6-monthly long-acting injectable and oral paliperidone in adults with schizophrenia.Journal of managed care & specialty pharmacy · 2023Article
- Article
- Association of current and past opioid use disorders with health-related quality of life and employment among US adults.Drug and alcohol dependence · 2019Article
- Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.Neuropsychiatric disease and treatment · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Robert A RosenheckDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Douglas L LeslieDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Kyaw J SintDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Haiqun LinDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Yue LiDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Joseph P McEvoyDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Matthew J ByerlyDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Robert M HamerDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Marvin S SwartzDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
T Scott StroupDr. Rosenheck is with the Department of Psychiatry, Yale Medical School, New Haven, Connecticut, and with the U.S. Department of Veterans Affairs New England Mental Illness Research, Education and Clinical Center, West Haven (e-mail: robert.rosenheck@yale.edu ). Dr. Leslie is with the Department of Public Health Sciences and Psychiatry, Penn State University College of Medicine, Hershey, Pennsylvania. Mr. Sint, Dr. Lin, and Mr. Li are with the Yale School of Public Health, New Haven, Connecticut. Dr. McEvoy is with the Medical College of Georgia, Georgia Regents University, Augusta. Dr. Byerly is with the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas. Dr. Hamer, who is deceased, was with the Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, at the time of this study. He was a beloved colleague, and we will miss his friendship, intelligence, and collegiality and will remember his special contributions to our field. Dr. Swartz is with the Department of Psychiatry, Duke University Medical Center, Durham, North Carolina. Dr. Stroup is with the Columbia University College of Physicians and Surgeons, New York.
Connecticut Mental Health Center · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M2/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMSR01MH081107 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STROUP, THOMAS SCOTT · 2009 to 2013
$10.7M1/2-A Comparison of Long-Acting Injectable Medications for Schizophrenia -ACLAIMSR01MH081234 · NIMH · DUKE UNIVERSITY · PI SWARTZ, MARVIN S · 2009 to 2013
$1.7MNCATS NIH HHS UL1 TR001863NIMH NIH HHS R01 MH081107NIMH NIH HHS R01 MH081234
Abstract
objectiveThis study assessed the relative cost-effectiveness of haloperidol decanoate (HD), a first-generation long-acting injectable (LAI) antipsychotic, and paliperidone palmitate (PP), a second-generation LAI antipsychotic.
methodsA double-blind, randomized 18-month clinical trial conducted at 22 clinical research sites in the United States compared the cost-effectiveness of HD and PP among 311 adults with schizophrenia or schizoaffective disorder who had been clinically assessed as likely to benefit from an LAI antipsychotic. Patients were randomly assigned to monthly intramuscular injections of HD (25-200 mg) or PP (39-234 mg) for up to 24 months. Quality-adjusted life years (QALYs) were measured by a schizophrenia-specific algorithm based on the Positive and Negative Syndrome Scale and side-effect assessments; total health care costs were assessed from the perspective of the health system.
resultsMixed-model analysis showed that PP was associated with .0297 greater QALYs over 18 months (p=.03) and with $2,100 more in average costs per quarter for inpatient and outpatient services and medication compared with HD (p<.001). Bootstrap analysis with 5,000 replications showed an incremental cost-effectiveness ratio for PP of $508,241 per QALY (95% confidence interval=$122,390-$1,582,711). Net health benefits analysis showed a .98 probability of greater cost-effectiveness for HD compared with PP at an estimated value of $150,000 per QALY and a .50 probability of greater cost-effectiveness at $500,000 per QALY.
conclusionsHD was more cost-effective than PP, suggesting that PP's slightly greater benefits did not justify its markedly higher costs, which are likely to fall once the medication's patent expires.
Indexed as
Cost-Benefit AnalysisOutcome Assessment, Health CareAdolescentAdultAgedAntipsychotic AgentsDelayed-Action PreparationsDouble-Blind MethodFemaleHaloperidolHumansInjectionsMaleMiddle AgedPaliperidone PalmitatePatient Acceptance of Health CareAntipsychotic AgentsDelayed-Action PreparationsHaloperidolhaloperidol decanoatePaliperidone Palmitate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT01136772ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.